Tech Optimist Episode 10—GLP-1: A VC’s Personal Experience

Alumni Ventures Founder and CEO Mike Collins shares his personal experience with Mounjaro

The Tech Optimist Podcast, presented by Alumni Ventures (AV), focuses on the intersection of technology, entrepreneurship, and innovation. True to our name, we are passionate about technology and its potential to drive positive change. We explore our lane through interviews with startup founders, venture investors, and futurists; discussions of new innovations; and reviews of trends in tech and venture capital. Subscribe Here »

In this episode, we interview AV Founders and CEO Mike Collins about his personal experience with Mounjaro. They discuss the drug’s impact on Mike’s health, the broader implications for the healthcare and investment sectors, and the future potential of GLP-1 treatments.

Alumni Ventures offers accredited individuals access to professional-grade venture capital, a key asset class missing from the portfolios of many sophisticated investors. Since 2014, AV has raised $1.3+ billion from 10,000+ investors and backed 1,300+ unique portfolio companies. AV is a top 20 venture firm in North America according to CB Insights, as well as the #1 most active venture firm in the U.S., and #3 most active in the world, according to PitchBook’s 2022 and 2023 rankings. AV has won awards from Inc. Magazine, Fast Company, Benzinga, and the US FinTech Awards.